ENVB - Intellia Therapeutics Anavex Life Sciences lead premarket gainers
Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s disease study.Beam Therapeutics (BEAM) +21%.Mexco Energy Corporation (MXC) +19%.Verve Therapeutics (VERV) +22%.Editas Medicine (EDIT) +19%.Arbutus Biopharma Corporation (ABUS) +14% after AB-729 shows robust and sustained HBsAg suppression in chronic HBV.CRISPR Therapeutics AG (CRSP) +13%.MannKind Corporation (MNKD) +13%.Dare Bioscience (DARE) +12% on a positive phase 1 results.Precision BioSciences (DTIL) +10% after first patient dosed in the combination arm of Precision BioSciences' Phase 1/2a trial evaluating PBCAR269A.Iterum Therapeutics (ITRM) +10%.Jiuzi Holdings (JZXN) +9%.Perion Network Ltd. (PERI) +10% on lifting guidance.Catabasis Pharmaceuticals (CATB) +9%.ChemoCentryx (CCXI) +9%.Enveric Biosciences (ENVB) +9%.Sangamo Therapeutics (SGMO) +9%.CEL-SCI Corporation (CVM) +8%.MediWound (MDWD) +8%.Bridgeline Digital (BLIN) +8%.Panbela Therapeutics (PBLA) +8%.Previously (June 28): Gene editing stocks take off as Intellia development slices through sector
For further details see:
Intellia Therapeutics, Anavex Life Sciences lead premarket gainers